Delhi High Court Upholds Ban on Triple-Drug Diabetes Combinations, Supreme Court to Review
Key Insights
Delhi High Court division bench restored the government's ban on fixed-dose combinations containing Glimepiride, Pioglitazone, and Metformin for Type 2 diabetes (search) treatment.
The court ruled that judges are "institutionally ill-equipped" to substitute expert medical assessment with judicial reasoning on drug safety matters.
Expert committee identified significant safety risks including hypoglycemia (search) and lack of combination-specific clinical data for the triple-drug formulations.
The Delhi High Court has upheld the central government's ban on controversial triple-drug combinations used to treat Type 2 diabetes (search), marking a significant victory for drug safety advocates and dealing a blow to pharmaceutical companies that had successfully challenged the prohibition in 2019.
Court Rules Against Judicial Overreach in Drug Safety
In a detailed 46-page judgment, the division bench firmly rejected a single-judge ruling that had previously set aside the ban, stating that judges are "institutionally ill-equipped" to decide on appropriate dosage of medicines or the scientific weight of research papers. The court emphasized that since an expert panel had already analyzed and concluded the banned combination drugs were risky, the single-judge bench should not have substituted "expert assessment" with its own "judicial reasoning."
The division bench ruled that the single judge had exceeded the "permissible limits of judicial review" by analyzing scientific data without independent scientific expertise, effectively acting as an "appeal" over an expert body's decision—a practice prohibited under constitutional law.
The Banned Drug Combinations
The case concerns fixed dose combinations (FDCs) containing three anti-diabetes drugs: Glimepiride, Pioglitazone, and Metformin. These formulations combine multiple active pharmaceutical ingredients in a single pill, often marketed for patient convenience.
Dr. Anoop Misra, chairman of Fortis C-DOC Hospital (search) for Diabetes and Allied Sciences, explained that three-drug combinations are not "rational." He noted that each drug has different characteristics and adverse effects profiles, and should ideally be given separately to monitor for side effects. Doses can be adjusted individually according to blood sugar levels, whereas increasing three-drug combinations automatically increases the dose of all three, which could be dangerous. "The only positive point is convenience," Dr. Misra stated, noting that he never uses FDCs.
Expert Committee Identifies Safety Risks
Following the Supreme Court's 2017 directive in Union of India v. Pfizer Limited, a Drugs Technical Advisory Board (DTAB) sub-committee conducted a comprehensive review. After examining 395 scientific publications and hearing submissions from drug manufacturers and public health groups, the committee recommended a complete ban on the triple-drug combinations.
The expert committee's conclusions were based on two key safety concerns. First was the risk of hypoglycemia (search), as the use of all three drugs together could dangerously lower blood sugar levels. Second, manufacturers failed to produce combination-specific safety data, relying instead on the safety profiles of individual drugs without demonstrating that the three-drug combination was safe as a single pill. The committee noted that such combinations were not accepted by international drug regulators.
Legal Timeline and Regulatory Framework
The controversy began in 2016 when the central government first banned 344 FDCs following recommendations by the Kokate Committee. On September 7, 2018, the government issued notifications specifically banning the triple-drug diabetes combinations.
In February 2019, a single-judge bench of the Delhi High Court quashed the government notifications, calling the ban "arbitrary." The judge reasoned that all three drugs were individually approved and recommended in standard diabetes treatment guidelines, and that taking one pill instead of three offered significant convenience to patients.
However, the division bench firmly rejected this reasoning as "fundamentally flawed." The court stated: "It cannot be presumed, as a matter of law or science, that individual drug components would behave, interact, or manifest identical safety profiles when administered in combination... Such a presumption is antithetical to the regulatory framework."
Regulatory Standards and Safety Thresholds
Under existing law, an FDC is treated as a "new drug," and manufacturers have a mandatory statutory obligation to independently establish its safety and efficacy—an obligation they failed to meet. Interpreting Section 26A of the Drugs and Cosmetics Act, 1940, the division bench held that the government does not need to wait for deaths or hospitalizations before acting.
"The statutory standard prescribed under Section 26A of the Drugs Act does not require the establishment of actual or proven harm to human beings," the court ruled. "The focus of the inquiry, therefore, is not on demonstrable injury but on the potential or foreseeable risk arising from continued use of the drug."
The division bench dismissed the "convenience" argument that had influenced the single-judge bench, ruling that while taking one pill is easier for patients, "convenience cannot supplant considerations of safety."
Supreme Court Review Pending
The legal battle continues as the Supreme Court has sought a response from the Centre and the Drug Controller General of India on an appeal by Micro Labs challenging the ban. The case involves multiple pharmaceutical companies including Lupin, Intas Pharmaceuticals, and Eris Lifesciences (search), all manufacturers of the banned FDCs.
The division bench's ruling has immediate effect, restoring prohibition on the manufacture, sale, and distribution of these triple-drug combinations. The decision represents a significant precedent for drug regulation, emphasizing that expert medical assessment takes precedence over judicial interpretation in matters of pharmaceutical safety.